In my twenty years of Class Ill medical device experience, I have not had the pleasure of working with a Chinese regulatory firm as talented and knowledgeable. As NMPA (CFDA) is increasing their technical and clinical review, it is one of the few companies staffed to assist medical device companies in this area. Their focus and dedicated support has exceeded our expectations. In my search for a strategic partner in China, they exceeded the other companies in all areas. While they have a very experienced Regulatory and Marketing team, their technical engineering, clinical, and international project management expertise place them above other companies in this area.

China Med Device (CMD) has brought a great deal of knowledge and understanding to our team to help us navigate the complexities of bringing a product to market in China. Specifically we have gained a much better understanding of the ins and outs of the China medical device market and choices of business models. CMD has walked us through the very complicated process NMPA (CFDA) registration guiding us not only from regulatory documentation and testing perspectives but also how the process will impact the reimbursement downstream

I had the opportunity to work with China Medical Device Group on a research project to inform our portfolio and regulatory strategy for entering the Chinese Marketplace. Grace's extensive experience in medical device has enabled her to independently and efficiently evaluate our product portfolio and assess our needs. They exceeded my expectations on quality and amount of data they were able to collect and we now have a strategy that has been informed by real data that will ultimately ensure our business success in the years to come.

China Med Device (CMD) has brought a great deal of knowledge and understanding to our team to help us navigate the complexities of bringing a product to market in China. Specifically we have gained a much better understanding of the ins and outs of the China medical device market and choices of business models. CMD has walked us through the very complicated process NMPA (CFDA) registration guiding us not only from regulatory documentation and testing perspectives but also how the process will impact the reimbursement downstream ...

On the fund raising front, what sets CMD apart is their understanding of the China market and key needs of Chinese investors. Their detail to preparation is second to none. Within a few months after our market access study, CMD was able to introduce us to solid investment sources.

We have been very impressed with CMD’s deep understanding of the medical device industry and investment landscape.